

# SAFETY DATA SHEET

according to the Globally Harmonized System



ORGANON

## Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51096-00021	Date of first issue: 23.01.2015

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mirtazapine Solid Formulation

#### Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

##### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

##### GHS Classification

Acute toxicity (Oral) : Category 5

Acute toxicity (Oral) : Category 5

Reproductive toxicity : Category 2

Specific target organ toxicity - : Category 2 (Nervous system)  
repeated exposure (Oral)

Short-term (acute) aquatic : Category 3  
hazard

Long-term (chronic) aquatic : Category 3  
hazard

##### GHS label elements

# SAFETY DATA SHEET

according to the Globally Harmonized System



ORGANON

## Mirtazapine Solid Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 51096-00021      Date of last issue: 04.04.2023  
Date of first issue: 23.01.2015

Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	H303 May be harmful if swallowed. H361fd Suspected of damaging fertility. Suspected of damaging the unborn child. H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed. H412 Harmful to aquatic life with long lasting effects.
Precautionary statements	:	<b>Prevention:</b> P203 Obtain, read and follow all safety instructions before use. P260 Do not breathe dust. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. <b>Response:</b> P301 + P317 IF SWALLOWED: Get medical help. P318 IF exposed or concerned, get medical advice. <b>Storage:</b> P405 Store locked up. <b>Disposal:</b> P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	>= 10 - < 20
Starch	9005-25-8	>= 10 - < 20

## 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Mirtazapine Solid Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 51096-00021      Date of last issue: 04.04.2023  
Date of first issue: 23.01.2015

---

If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May be harmful if swallowed. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

---

### 5. FIREFIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Silicon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : Use personal protective equipment.

---

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51096-00021	Date of first issue: 23.01.2015

- tive equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

# SAFETY DATA SHEET

according to the Globally Harmonized System



ORGANON

## Mirtazapine Solid Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 51096-00021      Date of last issue: 04.04.2023  
Date of first issue: 23.01.2015

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	ACGIH
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 µg/m <sup>3</sup>	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Ensure adequate ventilation, especially in confined areas.  
Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Eye protection** : Wear the following personal protective equipment:  
Safety goggles

**Skin and body protection** : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.  
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** : powder

**Colour** : No data available

# SAFETY DATA SHEET

according to the Globally Harmonized System



 ORGANON

## Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51096-00021	Date of first issue: 23.01.2015

---

Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Mirtazapine Solid Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 51096-00021      Date of last issue: 04.04.2023  
Date of first issue: 23.01.2015

Particle size : No data available

### 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

May be harmful if swallowed.

#### Product:

Acute oral toxicity : Acute toxicity estimate: 3,200 mg/kg  
Method: Calculation method

#### Components:

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

#### **Starch:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

#### **Skin corrosion/irritation**

Not classified based on available information.

#### **Serious eye damage/eye irritation**

Not classified based on available information.

#### Components:

#### **Starch:**

Species : Rabbit  
Result : No eye irritation

# SAFETY DATA SHEET

according to the Globally Harmonized System



ORGANON

## Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51096-00021	Date of first issue: 23.01.2015

---

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### Starch:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster lung cells Result: negative
		Test Type: unscheduled DNA synthesis assay Test system: mammalian cells Result: negative
		Test Type: sister chromatid exchange assay Test system: mammalian cells Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Rat Cell type: Bone marrow Application Route: Oral Result: negative

##### Starch:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

### Carcinogenicity

Not classified based on available information.



# SAFETY DATA SHEET

according to the Globally Harmonized System



ORGANON

## Mirtazapine Solid Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 51096-00021      Date of last issue: 04.04.2023  
Date of first issue: 23.01.2015

### Components:

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Mouse  
Application Route : Oral  
Exposure time : 18 month(s)  
LOAEL : 200 mg/kg body weight  
Result : equivocal  
Target Organs : Liver

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
LOAEL : 20 mg/kg body weight  
Result : equivocal  
Target Organs : Liver, Thyroid

### **Reproductive toxicity**

Suspected of damaging fertility. Suspected of damaging the unborn child.

### Components:

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: LOAEL: 15 mg/kg body weight  
Symptoms: Effect on estrous cycle, Increase of early resorptions  
Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 100 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 40 mg/kg body weight  
Result: No adverse effects, No teratogenic effects

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

### **STOT - single exposure**

Not classified based on available information.

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Mirtazapine Solid Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 51096-00021      Date of last issue: 04.04.2023  
Date of first issue: 23.01.2015

---

### STOT - repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

#### Components:

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Exposure routes : Ingestion  
Target Organs : Nervous system  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Rat  
LOAEL : 120 mg/kg  
Application Route : Oral  
Exposure time : 13 Weeks  
Target Organs : Nervous system

Species : Dog  
LOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 52 Weeks  
Target Organs : Nervous system  
Symptoms : Tremors

Species : Dog  
LOAEL : 20 mg/kg  
Application Route : Oral  
Exposure time : 13 Weeks  
Target Organs : Nervous system, Testis  
Symptoms : Tremors

#### **Starch:**

Species : Rat  
NOAEL : >= 2,000 mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Ingestion : Symptoms: Drowsiness, constipation, dry mouth, asthenia,

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51096-00021	Date of first issue: 23.01.2015

Dizziness, Disorientation

## 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l  
Exposure time: 96 h  
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 19.5 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 ( Pseudokirchneriella subcapitata (green algae)): 5.7 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC ( Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 3.6 mg/l  
Exposure time: 31 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.32 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

### **Persistence and degradability**

No data available

### **Bioaccumulative potential**

#### Components:

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51096-00021	Date of first issue: 23.01.2015

---

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)  
Bioconcentration factor (BCF): 334  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 2.78

### Mobility in soil

#### Components:

**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Distribution among environmental compartments : log Koc: 4.48

#### **Other adverse effects**

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

#### **Transport in bulk according to IMO instruments**

Not applicable for product as supplied.

#### **Special precautions for user**

Not applicable

---

## 15. REGULATORY INFORMATION

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

**The components of this product are reported in the following inventories:**

---

# SAFETY DATA SHEET

according to the Globally Harmonized System



ORGANON

## Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51096-00021	Date of first issue: 23.01.2015

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 16. OTHER INFORMATION

Revision Date : 30.09.2023

#### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	51096-00021	Date of first issue: 23.01.2015

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN